Abstract:ObjectiveTo investigate the value of interleukin-6 (IL-6) combined with Model for End-stage Liver Disease (MELD) score in predicting the prognosis of patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (HBV-ACLF). MethodsA total of 86 patients with HBV-ACLF who were hospitalized in The First Affiliated Hospital of Soochow University from January 2015 to December 2018 were enrolled, and according to their survival status after follow-up for 90 days, they were divided into death group with 50 patients and survival group with 36 patients. ELISA was used to measure the serum level of IL-6, and a statistical analysis was performed for general information. The t-test was used for comparison of normally distributed continuous data between groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test was used for comparison of categorical data between two groups. A Pearson correlation analysis was performed for IL-6 and other variables; a binary logistic regression analysis was used to investigate the independent risk factors for the prognosis of patients with HBV-ACLF; the receiver operating characteristic (ROC) curve was used to assess the value of IL-6 combined with MELD score in predicting the prognosis of HBV-ACLF. ResultsThere were significant differences between the death group and the survival group in hematocrit (t=2.413), platelet count (t=6.584), total bilirubin (TBil) (t=-8.070), prothrombin time (PT) (U=77.500), international standardized ratio (U=102000), HBV DNA (t=-2.767), IL-6 (t=-16.543), and MELD score (t=-8.192), and the death group had a significantly higher level of IL-6 than the survival group (27.13±12.18 pg/mL vs 9.72±5.56 pg/mL, P＜0.001). The Pearson correlation analysis showed that IL-6 was positively correlated with TBil and PT (r=0.579 and 0.681, both P＜0.001). The binary logistic regression analysis showed that IL-6 (odds ratio［OR］=1.480, 95% confidence interval ［CI］: 1.196~1.833, P=0.007) and MELD score (OR=1128, 95%CI: 1.033~1.231, P＜0.001) were independent risk factors for the death of HBV-ACLF patients within 90 days. IL-6 combined with MELD score had an area under the ROC curve (AUC) of 0.891 (95%CI: 0.778~0.999), with a higher AUC than IL-6 (AUC=0.838, 95%CI: 0.687~0.989) or MELD score (AUC=0.783, 95%CI: 0.634~0.933). IL-6 combined with MELD score had a significantly higher value than IL-6 alone in predicting the prognosis of patients with HBV-ACLF (Z=-2.257, P=0.024). ConclusionIL-6 combined with MELD score can be used as a good model for predicting the short-term prognosis of patients with HBV-ACLF.

Value of HBsAg quantification in predicting the prognosis of patients with chronic severe hepatitis B

[Relationship between the quantitative results of HBV DNA and HBV markers (HBV M) in population with low-level HBsAg].

Serum ceruloplasmin level in predicting 30-day outcome of hepatitis B virus-related acute-on-chronic liver failure

HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients

HBsAg Levels in HBeAg-positive Chronic Hepatitis B Patients with Different Immune Conditions.

The Impact of HBeAg Positivity/negativity and HBV DNA Loads on the Prognosis of Chronic Severe Hepatitis B

Quantitative HBsAg versus HBV DNA in Predicting Significant Hepatitis Activity of HBeAg-Positive Chronic HBV Infection

The Role of Hepatitis B Core-Related Antigen in Predicting Hepatitis B Virus Recurrence after Liver Transplantation.

Prognostic Value of Anti‐hbc Quantification in Hepatitis B Virus Related Acute‐on‐chronic Liver Failure

Value of interleukin-6 combined with Model for End-Stage Liver Disease score in predicting the prognosis of hepa-titis B virus-related acute-on-chronic liver failure

Role of Serum Hepatitis B Virus Marker Quantitation to Differentiate Natural History

Efficacy of serum HBsAg levels by two quantitative methods in predicting liver histopathological grading and staging in patients with chronic hepatitis B

Quantitative hepatitis B core antibody levels can be used as a predictive index of HBsAg clearance

Effect of Serum Hepatitis B Surface Antigen Levels on Predicting the Clinical Outcomes of Chronic Hepatitis B Infection: A Meta‐analysis

The value of serum HBsAg and HBeAg quantification in predicting response of interferon α 1b treatment in patients with HBeAg-positive chronic hepatitis B

Evaluation of serum HBsAg, HBcrAg and HBV DNA in prediction of the pathological status of liver in patients with chronic hepatitis B

Clinical Implications of Hepatitis B Surface Antigen Quantitation in the Natural History of Chronic Hepatitis B Virus Infection.

Relationship between HBsAg level and HBV DNA level as well as illness severity in patients with HBV-related acute-on-chronk liver failure

Level of hepatitis B surface antigen might serve as a new marker to predict hepatocellular carcinoma recurrence following curative resection in patients with low viral load.

HBsAg Quantitative Value in Different Stages of Hepatitis B Virus Infection and Its Correlations with Serum HBV DNA and Age

A Predictive Model to Evaluate the HbeAg Positivity of Chronic Hepatitis B Virus Patients in Clinics: A Cross-Sectional Study